Ignite Creation Date:
2024-05-06 @ 4:26 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04982354
Status:
WITHDRAWN
Last Update Posted:
2024-04-09
First Post:
2021-07-13
Brief Title:
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Sponsor:
Guenther Koehne
Organization:
Baptist Health South Florida
Study Overview
Official Title:
A Pilot Study of Daunorubicin-cytarabine Liposome CPX-351 Plus FLT3-inhibitor Midostaurin as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34-Selected Allograft
Status:
WITHDRAWN
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Could not accrue
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome CPX-351 in combination with a FLT3-inhibitor midostaurin as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia AML and subsequent CD34-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None